PPARG and amyloidosis: Interestingly, therapeutic application of the PPARγ agonists, pioglitazone, has been demonstrated to skew microglia from M1 to the M2 phenotype, reduce amyloid plaque burden, and improve cognitive deficits in the APP/PS1 mouse model of AD [80].